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Acute coronary events result from the rupture of an athero- 
sclerotic plaque, leading to formation of an occlusive coronaff 
thrombus. Recent developments in the field of gene transfer 
provide the opportunity to genetically modify cells involved in 
plaque rupture as well as thrombus formation and thus prevent 
acute coronary syndromes. A first approach consists of transfer- 
ring genes, the product of which may stabilize the vulnerable 
plaque by reducing the plaque content in lipids and macrophages. 
Alternatively, the introduction into the atherosclerotic plaque of 
genes encoding for thrombolytic proteins or growth factors able to 
restore physiologic antithrombotic functions of endothelial cells 
may inhibit thrombus formation should the plaque rupture. The 
success of such strategies depends on the efficiency with which the 
transgene is introduced and expressed into the target cell, the 
duration of transgene xpression and the ability of the transgene 
product to ultimately prevent plaque rupture or thrombus forma- 
tion, or both. 
(J Am Coil Cardiol 1995;26:826-35) 
Rupture of coronary atherosclerotic plaque and subsequcnt 
formation of an occlusive intracoronary thrombus (Fig, 1) are 
the major events precipitating acute coronary syndromes (1- 
6). The vulnerable plaque is smaller in size (7), richer in lipids 
(1,2) and more infiltrated with macrophages (2,3,8-10) than 
the stable fibromuscular lesion. Therefore, lowering the lipid 
or macrophage pools stored in the plaque may "stabilize" the 
plaque and reduce the incidence of plaque rupture (2,4-6). 
Indeed, cholesterol-lowering trials have yielded a significant 
reduction in acute cardiac events (11-18). Antithrombotic 
therapies may further prevent acute coronary syndromes by 
altering the consequences of plaque rupture (4). 
Recent advances in the field of molecular biology, com- 
bined with the development of efficient vectors to perform in 
vivo gene transfer, have led to the emergence of novel thera- 
pies to prevent acute coronary syndromes. Because gone 
therapy, in contrast o drug therapy, implies a variable and 
currently undetermined time interval for the transgene to be 
expressed, certain gene therapy approaches ultimately may not 
be appropriate for the treatment ofpatients with acute infarc- 
tion. Genetic interventions that arc designed to stabilize the 
vulnerable plaque or inhibit thrombus formation (Table 1), 
however, hold considerable promise and are the subject of this 
review. 
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Gene Therapy  fo r  the  Vu lnerab le  P laque  
Lowering the level of plasma cholesterol may reduce pro- 
grcssion, and even induce regression, of atherosclerotic lesions 
(11-19). This phenomenon appears to represent the conse- 
quence of reducing plasma low density lipoprotein (LDL) 
levels as well as increasing plasma high density lipoprotein 
(HDL) levels. Even modest changes in coronary lumen diam- 
eter, observed in patients as a result of lipid-lowering interven- 
tions, have been associated with a substantial reduction in the 
incidence of acute coronary syndromes (11-18). It is possible 
that this beneficial effect was due to the regression of plaques 
rich in cholesterol and macrophages (i.e., plaques prone to 
rupture) (4,19). Therefore, therapeutic strategies aimed at 1) 
lowering plasma LDL, 2) increasing plasma HDL, or 3) 
mitigating macrophage infiltration hold promise for reducing 
the mortality and morbidity associated with coronary athero- 
sclerosis. 
Familial H)7)ercholesterolemia: A Model for 
LDL- Targeted Gene Therapy 
Familial hypercholesterolemia is caused by a genetic defi- 
ciency in the hepatic receptors for LDL cholesterol and is 
associated with severe hypercholesterolemia and premature 
coronary artery disease (20). The observation that orthotopic 
liver transplantation from donors who express normal LDE 
rcceptor activity may lead to complete correction of the 
dyslipidemia in homozygotes (21) set the stage for a genetic 
strategy, first articulated by Goldstein et al. (22), geared 
toward introduction of normal LDL receptor genes into the 
liver. 
Two different approaches to gene therapy have been devel- 
oped for familial hypercholesterolemia. In the first approach, 
referred to as ex vivo (or "indirect") gene transfer, ceils are 
removed, transduced ex vivo with the LDL receptor gene, then 
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Figure l. Cross ection of a ruptured atherosclerotic plaque from an 
infarct-related corona~, artery. 
transplanted back into the liver, in thc second approach, 
referred to as in vivo (or "'direct") gene transfer, thc LDL 
receptor gene is directly introduced into the liver during a 
one-step rocedure. Although familial hypercholesterolemia is 
found in only a small minority of patients, the promise of 
genetically increasing LDL receptor abundance in the liver 
may have implications for treating more common forms of 
hypercholesterolemia, and thereby potentially reducing the 
incidence of acute corona~ syndromes in these patients (23). 
Ex vivo gene therapy for familial hypercholesterolemia. 
Wilson et al. (24) and Chowdhury et al. (25) used an animal 
model for familial hypercholesterolemia, theWatanabe heri- 
table hyperlipidemic (WHHL) rabbit, to isolate hepatocytes 
after partial hepatectomy, transfect these cells ex vivo with 
replication-defective retroviruses including an LDL receptor 
complementary deoxyribonucleic acid (eDNA) and implant 
the transduced hepatocytes into the liver of recipient WHHL 
rabbits. Stable expression of the recombinant LDL receptor 
Table 1. Potential Targets for Genetic Interventions to Prevcnl 
Acute Coronary Syndromes 
Target Gene Intcr~ention Mechanisms 
LDL rcceptor Augmentation Plaque stahilization 
HDL Augmentation Plaque stahilizatioa 
eNOS Augmentation Plaque stabilization, inhibition of 
SMC proliferation, inhihition 
of thrombus formation 
sVCAM-I Augmentation Plaque stabilization 
Mctalloproteinascs [nhibititm Plaque stabilization 
t-PA Augmentatian Inhibition of thrombus formation 
scu-PA Augmentation Inhibition of thrombus formation 
VEGF Augmentation Inhibition of thrombus 
tbrmation, inhibition of SM(" 
proliferation 
eNOS constitutive ndothclial nitric oxide synthase: HDL high density 
lipoprotein: LDL low density lipoprotein; scu-PA = singlc-chain urokinasc 
plasminogcn activator: SMC - smooth muscle cells; sVCAM-1 : soluble 
vascular cell adhesion molecule I: t-PA tissue-type plasminogen acti',,ator: 
VEGF - vascular endothelial growth factor. 
gene as well as a consistent decrease inserum cholesterol could 
be detected for several months after autologous transplanta- 
tion (25). 
On the basis of these encouraging results, the first clinical 
trial of gene therapy to treat patients with homozygous familial 
hypercholesterolemia was initiated in 1992 (26). In this proto- 
col, an ex vivo approach similar to the one used in the WHHL 
rabbit was adopted. After partial hepatectomy, hepatocytes 
were released and transfected ex vivo with recombinant retro- 
viruses expressing a human LDL receptor cDNA. Transduced 
hepatocytes were subsequently infused irectly into the portal 
circulation to allow engraftment of LDL receptor-expressing 
hepatocytes in the liver. Preliminary results from the first 
patient enrolled in this trial were recently published (27). The 
patient tolerated the surgical procedure well, and expression of 
the transfected LDL receptor gene was documented 4 months 
after gene transfer in 1:103 to [:104 liver cells. This was 
paralleled by a 17% decrease inserum LDL that persisted for 
at least 18 months. 
These seminal results are the subject of ongoing clinical and 
laboratory investigations. Brown et al. (28) have outlined three 
major issues that remain to be addressed regarding gene 
therapy for familial hypercholesterolemia: 1) It is unclear 
whether the observed reduction in serum LDL was due to an 
actual increase in LDL receptor activity or a reduction i  LDL 
production in response to liver surgery. Study of LDL clear- 
ance, rather than LDL levels, may help to answer this question. 
2) It must be established that the reduction in serum LDL 
resulted from expression of the exogenous LDL receptor gene, 
rather than from up-regulation of the patient's own residual 
LDL-receptor activity, induced, in this case, by the surgical 
procedure itself (29) or by lovastatin therapy, or both (28). 
3) Clinical application of ex vivo gene therapy may be limited 
by the surgical hazard, the costly and time-consuming proce- 
dures required for ex vivo transfection and by the fact that 
most hepatocytes lose their capacity for reintroduction after ex 
vivo transfection. 
In vivo gene therapy for familial hypereholesterolemia. 
According to the ideal paradigm for in vivo gene therapy, a 
vector expressing a normal LDL receptor gene would be 
directly injected into the liver as an atraumatic, one-step 
procedure. However, efficient gene transfer in vivo has been 
difficult to achieve using retroviral vectors because mitotic 
activity is required to facilitate retrovirus-mediated transfec- 
tion (30), and hepatocytes are typically quiescent under normal 
physiologic conditions. Therefore, vectors capable of transduc- 
ing nondividing cells, namely recombinant adenoviruses and 
molecular conjugates, have been investigated for this purpose. 
Several features of recombinant adenoviruses suggest that 
they might be appropriate vehicles for human gene therapies, 
in general, and liver-directed gene therapy, in particular (23). 
Indeed, recombinant adenoviruses can be rendered efective 
for replication by deleting early sequences E1A and E1B from 
their genome. They do not integrate into the genome of 
transfected cells, thus reducing the risk of insertional mutagen- 
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esis; they can be produced at high titers; and they accommo- 
date relatively large cDNA inserts (up to 7.5 kilobases [kb]). 
These theoretic onsiderations have been translated into 
successful experimental studies. Indeed, intravenous or intra- 
portal introduction of adenoviruses xpressing a human LDL 
receptor cDNA in normal mice (31), knockout mice lacking 
functional LDL receptor genes (32) and WHHL rabbits (33) 
results in extremely efficient liver transfection, as well as 
increased LDL clearance or decreased LDL levels, or both. 
However, effects were transient, lasting <3 weeks. The rela- 
tively rapid diminution in transgene xpression may involve a 
T-lymphocyte-mediated immune response toward certain viral 
proteins (34). In the case of hypercholesterolemia, such tran- 
sient expression of the therapeutic gene is a major drawback of 
gene transfer strategies based on "first-generation" adenovi- 
ruses. Repeated administration of the same vector may not 
represent a simple solution to more protracted expression, 
given the additional evidence of antibody-mediated r uction 
in gene expression on subsequent exposures to the adenovirus 
(33). Recent reports (35,36) suggest that insertion of a 
temperature-sensitive mutation within the E2A region of the 
adenoviral genome results in less immunogenic vectors and 
prolonged transgene xpression at permissive temperatures. 
The effect of further deletions within the E2 and E4 regions on 
time course of gene expression iscurrently under investigation. 
Molecular conjugates have been recently used to perform 
liver-directed gene transfer in vivo (37). A DNA-protein 
complex, containing an LDL receptor cDNA complexed to a 
protein conjugate, was injected systemically into WHHL rab- 
bits. The protein conjugate incorporates a ligand (asialo- 
orosomucoid) for the hepatocyte-specific asialoglycoprotein 
receptor, which is covalently attached to the polycation ~- 
polylysine. In this system, referred to as receptor-mediated 
gene transfer, liver transfection ismediated by the interaction 
between asialo-orosomucoid and its receptor. Total serum 
cholesterol was decreased substantially after gene transfer but 
returned to baseline in <6 days. The nonviral nature of the 
DNA-protein complex and the noninvasive approach for gene 
delivery, nevertheless, remain attractive features for clinical 
application. Alternatively, the coupling of molecular conju- 
gates to adenoviral particles has been shown to increase the 
efficiency of in vitro hepato~te gene transfer over that ob- 
tained by conjugates alone by promoting DNA escape from 
lysosomal hydrolysis (38). 
HDL Cholesterol." A New Target for Gene Therapy 
Previous studies (39-41) have established an inverse cor- 
relation between plasma levels of HDL and the incidence of 
coronary artery disease. In several lipid-lowering clinical trials, 
an increase in serum HDL was correlated with a reduction in 
the incidence of acute coronary syndromes, and sometimes 
with a reduction in progression or slight regression of angio- 
graphic evidence of coronary atherosclerosis (12,14,16,42). 
Taken together, these results suggest hat therapies that in- 
crease serum HDL may have an antiatherogenic effect. Indeed, 
Badimon et al. (43) showed that intravenous administration of
HDL not only inhibited the formation but also induced 
regression (44) of established fatty streaks. More recently, 
Rubin et al. (45) developed a transgenic mouse gene that 
overexpresses apo-Al, the major protein component of HDL, 
and the mice are protected from the development of early 
atherosclerotic lesions (46). The mechanism of the protective 
effect of HDL is still unclear. It has been postulated that HDL 
may reduce the amount of cholesterol entering the plaque and 
promote clearance of cholesterol deposits from the plaque 
(47). Alternatively, intravenous injection of apo-Al in the 
hyperchotesterolemic rabbit reduces intimal thickening in- 
duced by arterial injury and is associated with a 50% reduction 
in neointimal macrophage content (48,49). Therefore, high 
serum HDL might be expected to induce regression of lipid- 
and macrophage-rich plaques, and ultimately reduce the risk of 
plaque rupture. Overexpression f apo-A1 by means of gene 
therapy has been recently reported in mice in which intrave- 
nous injection of an apo-Al-expressing adenovirus transiently 
increased serum HDL to a level comparable to that shown to 
be protective in humans (50). Such an approach olds promise 
for fitture development of gene therapy strategies targeted 
toward stabilization of the vulnerable plaque through HDL- 
mediated lipid or macrophage r moval, or both. 
Future Directions: Targeting the Macrophage 
Certain studies (10) have suggested that unstable plaque 
may be comprised of abundant macrophages (Fig. 2), espe- 
cially at the margins of the plaque (3). Macrophages release 
lytic en~mes as well as matrix metalloproteinases (51,52) (Fig. 
3) that may be responsible for fibrous cap weakening and 
subsequent plaque rupture (6,10,53). The association between 
macrophages and plaque rupture has been strengthened bythe 
recent observation of a 92-kDa metalloproteinase in carotid 
endarterectomy specimens (51) and coronary lesions of pa- 
tients with unstable angina (52); and the finding that incuba- 
tion of atherosclerotic f brous caps with macrophages in vitro 
increased collagen breakdown (54). It is therefore conceivable 
that reducing macrophage infiltration may potentially reduce 
the risk of plaque rupture. 
A first approach as been developed by Chert et al., in 
which a recombinant adenovirus expressing a soluble form of 
the vascular cell adhesion molecule VCAM-1 (sVCAM-1) is 
transferred into porcine vein grafts ex vivo (55). Vein grafts, 
interposed as vascular grafts in the carotid arteries, were shown 
to express high levels of sVCAM-1 three days after implanta- 
tion. These findings suggest the possibility that high level 
sVCAM-I expression may be exploited to competitively inhibit 
interaction between endothelial VCAM-1 and its very late 
antigen (VLA)-4 counterpart a the surface of circulating mono- 
cytes, thereby preventing macrophage infiltration of the graft. 
Alternatively, preliminary findings indicate that nitric oxide 
inhibits monocyte chemotactic activity of the endothelium by 
down-regulating the cytokine monocyte chemoattractant 
protein-1 (MCP-1) at the transcriptional level (56). If these 
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Figure 2. Immunohistochemical staining with monoclonal antibody to
HAM56, a macrophage marker, of an atherectomy specimen from a 
patient with unstable angina. ×20{I, reduced by 20%. 
data are confirmed, it is likely that secretion of high levels of 
nitric oxide in the vicinity of an atherosclerotic plaque may 
reduce macrophage r cruitment into the plaque. In this case, 
the antithrombotic, antiproliferative and vasorelaxing activities 
of nitric oxide (57) may also facilitate plaque passivation. One 
way to increase local levels of nitric oxide is to transfer into the 
atherosclerotic lesion the gene encoding for constitutive endo- 
thelial nitric oxide synthase (58). It has been recently reported 
that the transfer of an endothelial nitric oxide synthase cDNA 
packaged into a liposome-Sendai virus carrier inhibits neoin- 
timal formation after balloon injury of the rat carotid arte~' 
(59). However, it is still speculative whether such a strategy will 
limit macrophage recruitment through down-regulation of 
MCP-1 because many other cytokines as well as oxidized LDLs 
may act as monocyte chemoattractants and participate in 
up-regulation of monocyte or endothelial cell adhesion mole- 
cules, or both (5). Moreover, the potential toxicity associated 
with local secretion of high levels of nitric oxide in the arterial 
wall, resulting in further LDL oxidation, remains to be ad- 
dressed (5). 
Arterial Gene Transfer: Contribution to 
Antithrombotic Strategies 
When plaque ruptures, the development of an occlusive 
thrombus plays a major part in determining the clinical pre- 
sentation in acute coronary syndromes (153,60-62). Indeed, 
Figure 3. Atherectomy specimen obtained from a patient with unsta- 
ble angina, immunostained for 92-kDa gelatinase. Arrows indicate 
sites of positive intracellular staining, x200, reduced by 20%. 
antithrombotic agents such as aspirin have been shown to 
reduce the risk of myocardial infarction (63,64). In the past, 
administration of antithrombotic therapies was achieved 
through a systemic route, enhancing the risk of hemorrhagic 
complications. Because of the focal nature of atherosclerosis, 
local delivery of antithrombotic agents at the site of the culprit 
lesion constitutes a logical alternative to systemic antithrom- 
botic therapies. High concentrations of a pharmacologic agent 
can thus be achieved in the vicinity of the atherosclerotic lesion 
with a reduced risk of systemic toxicity (65,66). However, 
pharmacologic agents with antithrombotic activity do not 
address the biologic mechanisms ofthrombosis. Some of these 
mechanisms involve aberrant endothelial gene expression (67). 
Specifically, increased expression of prothrombotic molecules, 
such as plasminogen activator inhibitor type-1 (68), or de- 
creased expression of an antithrombotic compound, such as 
tissue-type plasminogen activator (t-PA) (69), by the diseased 
endothelium ay facilitate the development of an occlusive 
thrombus at the site of plaque rupture. These observations 
suggest a rationale for the application of gene therapy to 
restore or augment antithrombotic endothelial cell function 
(70). 
Feasibility of Arterial Gene Transfer Targeted 
Toward the Endothelium 
As previously described in the liver, two different ap- 
proaches have been used to perform arterial gene transfer. Ex 
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vivo gene transfer has been used to seed endothclium-denuded 
arteries, prosthetic vascular grafts and stents with genetically 
modified endothelial cells. In vivo gene transfer, in contrast, 
involves direct introduction ofgenetic material into the arterial 
wall. 
Ex vivo gene transfer to native arteries. Nabel et al. (71) 
first demonstrated that genetically engineered endothelial cells 
could be introduced into the arterial wall and there express a
recombinant gene. In that study, porcine endothelial cells were 
transfected in vitro with a retroviral vector expressing a
recombinant beta-galactosidase gene. Successfully transfected 
cells were then introduced into denuded iliofemoral arteries of 
syngeneic animals using a double-balloon catheter. After this 
procedure, 2% to 11% of transduced endothelial cells attached 
to the arterial wall. Of these cells, 20% to 100% expressed 
beta-galactosidase up to 4 weeks after gene transfer. 
Ex vivo gene transfer to vascular prosthetic devices. Con- 
ventional use of grafts and stents has been compromised bythe 
risk of acute thrombosis, predominantly during the first weeks 
after implantation (72), the time window required for endo- 
thelialization of the prosthetic material. Endothelial ceils 
genetically engineered to produce antithrombotic molecules 
were therefore investigated as a means of favorably influencing 
the patency of such prosthetic devices. 
Wilson et al. (73), for example, used Dacron grafts coated 
with genetically modified endothelial cells as carotid interpo- 
sition grafts in a canine model. In that model, endothelial cells 
were transfected in vitro using a rctroviral vector expressing a 
beta-galactosidase gene before graft coating. By 5 weeks after 
implantation, the lumen aspect of the graft was covered by a 
monolayer of endothelial cells, some of which expressed the 
beta-galactosidase gone. On the basis of these results, Wilson 
et al. proposed that endothelial cells may be genetically 
modified to secrete antithrombotic proteins and thereby im- 
prove vascular graft patency. Successful implantation of in 
vitro, endothelialized, polytetrafluoroethylene, femorotibial 
grafts in four patients, resulting in 100% patency 3 months 
after implantation (74), suggests the feasibility of using this 
strategy to bypass medium-sized arteries. 
The risk of acute or subacute thrombosis after implantation 
of coronary stents remains amajor issue for the interventional 
cardiologist (72). Aggressive systemic antithrombotic treat- 
ment may not be optimal for prevention of stent occlusion 
because it is accompanied by increased bleeding complications, 
extended hospital stay and increased cost (75). Seeding of 
arterial stents with endothelial cells before implantation has 
been proposed as an alternative strategy (76). Because the 
antithrombotic a tivity of seeded endothelial cells may be 
altered, Dichek et al. (77) seeded stents with endothelial ceils 
genetically engineered to express a human t-PA gene. A 
significant percent of transfected endothelial cells remained 
adherent to the stent after in vitro balloon-mediated stent 
expansion (77) and subsequent exposure to pulsatile flow (78). 
However, long-term adherencc of the seeded cells under 
variable in vivo flow conditions remains a concern. 
Ex vivo gene transfer to vein grafts. Early vein graft 
thrombosis as well as accelerated graft atherosclerosis l mits 
the long-term efficacy of aortocoronary b pass urgery (79). 
Systemic delivery of antiplatelet agents has been shown (80) to 
reduce the incidence of graft occlusion by nearly 50%. Ex vivo 
manipulation of vein grafts, however, provides a unique op- 
portunity for local therapy to be applied to the graft before 
implantation. One attractive approach would be to transfect 
freshly explanted vein grafts with a foreign gene encoding an 
antithrombotic protein. As indicated previously, ex vivo, 
adenovirus-mediated, vein graft transfection is feasible and 
results in relatively high level recombinant protein secretion 
(55). However, successful introduction ofantithrombotic genes 
in vein grafts has not yet been reported. 
In vivo arterial gene transfer. Since Nabel et al. (81) first 
demonstrated that direct introduction of a foreign gene into a 
specific arterial segment could be performed in live animals, 
the field of in vivo arterial gene transfer has evolved rapidly. As 
recently depicted by Leclerc and Isner (82), strategies aimed at 
introducing foreign genetic material into the arterial wall in 
live animals involve a macrodelivery system (the gun) to 
transport the foreign gene to the arterial target site, a vector of 
gene transfer (the bullet) to facilitate the cellular uptake of the 
transgene and a molecular mechanism (the target) with which 
the product of the transgene will ultimately interact. 
The guns. Earlier techniques designed to perform arterial 
gcne transfer included those which relied on direct introduc- 
tion of the transgene to a surgically exposed, isolated arterial 
segment (83-87). Although this method is likely to optimize 
the efficiency of gene transfer, the invasive nature of this 
approach clearly limits its clinical applicability. 
An alternative approach involves catheter-based, local de- 
live D' of the foreign gene to a specific arterial segment. In their 
seminal work, Nabel et al. (81) introduced a double-balloon 
catheter into porcine iliofemoral arteries through aside branch 
under direct vision. Sequential inflation of the two balloons 
isolated an arterial segment in which a solution containing 
retroviral vectors or liposomes was instilled, allowed to incu- 
bate then retrieved before restoration of flow. Since these 
pioneering experiments, other delivery catheters have been 
developed (see [66] for a review), and different groups have 
reported entirely percutaneous approaches (88-91). 
The bullets. Several vectors have been used to facilitate 
cellular uptake of the transgene into the arterial wall. Studies 
of cationic liposomes (81,83,92,93) and retroviruses (81,94) 
were first used to demonstrate that arterial gene transfer was 
feasible. However, transfection efficiencies using these vectors 
were extremely low (typically <1:10 ~' cells expressed the trans- 
gene). Similar results were reported when DNA with no 
vehicle ("naked" DNA) was used (Fig. 4) (95). 
Replication-defective, r combinant adenoviruses represent 
an alternative to liposome- or retrovirus-based arterial gene 
transfer (23). Several groups have recently reported (85,86,96) 
highly efficient adenovirus-mediated arterial transfection, us- 
ing either an intraoperative route or a percutaneous approach 
(88-91,97-99). Transfection efficiencies achieved using adeno- 
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Figure 4. Gene transfer to the rabbit iliac artery using DNA alone 
("naked DNA"). A plasmid coding for nuclear-specific beta- 
galactosidase was applied to the surface of a hydrogel-coated balloon 
catheter and expressed into the arterial wall during balloon catheter 
inflation. Double labeling for nuclear bett,-galactosidase (blue [ar- 
rows]) and cytoplasmic smooth muscle alpha-actin (brown). Only rare 
medial smooth muscle cells show evidence of successful transfection 
(blue). Reproduced from Riessen et al. (95), with permission. 
viruses are at least three logs higher than those reported using 
liposomes (93,99) and retroviruses (81). Important drawbacks 
of adenoviral vectors, however, include transient ransgene 
expression, typically limited to 2 to 3 weeks after gene transfer 
(as discussed earlier), and the risk of systemic dissemination 
facilitated by the amphotropic haracter of the adenovirus. 
Reports have varied with regard to extraarterial distribution of 
adenoviral vectors after percutaneous local delivery (90,91,97- 
99). These discrepancies may be related to the specific local 
delivery device used for gene transfer. Indeed extra-arterial 
transfection has been reported with the double-balloon (90,98) 
and porous balloon catheters (97,99) but not with the 
hydrogel-coated balloon catheter (9(i). Finally, we recently 
reported (91) that the efficiency of adenovirus-mediated gene 
transfer is reduced in atherosclerotic versus normal arteries. 
However, transfection efficiency achicvcd in atherosclerotic 
arteries with adenoviruses i  still several orders of magnitude 
higher than that achieved using liposomes (99). 
In vivo transfection of the endothelium has been achieved 
using intraoperative (85,86,88) or catheter-based (81,88- 
90,100,101 ) delivery of retroviral (81) or adenoviral (85,86,88- 
90,101) vectors. Exposure of a nondenuded, normal peripheral 
artery to adenoviral vectors results in gene expression that 
is limited to the endothelium (85,86,88-90,101) (Fig. 5A). 
Conversely, arterial de-endothelialization at the time of 
adenovirus-mediated gene transfer esults in efficient medial 
smooth muscle cell transfection (Fig. 5B) (86-88,90,98,102,103). 
Taken together, these findings suggest that l) cell-specific gene 
transfer targeted toward the endothelium is feasible when 
adenoviruses are used as vectors; and 2) tin intact endothelium 
constitutes a potential physical barrier to adenovirus penetra- 
tion into the media of peripheral arteries. However, a recent 
Figure 5. Percutaneous adenovirus-mediated arterial gene transfer. 
A recombinant adenovirus expressing a nuclear-specific beta- 
galactosidase was delivered locally into the rabbit iliac artery using 
either a double-balloon (A) or a hydrogel-coated balloon catheter (B). 
Beta-galactosidase activity is revealed by X-gal staining (blue). A, 
Gene transfer is confined to the endothelium when the artery is intact. 
Note the presence of one superficial medial cell expressing beta- 
galactosidase (arrow) just below a site of focal disruption of the 
endotheIium. B, The endothelial layer is removed at the time of 
transfection. A nearly continuous uperficial layer of transfected 
medial smooth muscle cells is observed below a well preserved internal 
elastic lamina (arrowheads). A = adventitia; L lumen; M = media. 
Adapted from Steg et al. (90), with permission. 
report by Barr et al. (100) suggests that intracoronary infusion 
of adenoviral vectors results in substantial medial as well as 
myocardial transfection, in addition to predominant endothe- 
lial transfection (100). This discrepancy may be due to struc- 
tural differences between peripheral and coronary arteries. In 
contrast, very low level gene transfer to all the layers of the 
arterial wall was observed after local delivery of liposomes or 
retroviral vectors using a double-balloon catheter (81). There- 
fore, recombinant adenoviruses currently appear to be the 
most appropriate vector with which to perform endothelium- 
specific arterial gene transfer. 
Current approaches for a genetic intervention to prevent 
thrombus formation. The demonstration that site-specific 
gene transfer to the vascular endothelium is feasible set the 
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stage for the development of genetic strategies aimed at 
preventing acute coronary syndromes. Dichek et al. (104) 
proposed that arterial thrombosis might be prevented by 
altering certain endothelial functions at the site of endothelial 
injury or dysfunction. One approach by which normal anti- 
thrombotic activity of the endothelium ight be restored 
involves transfection of the t-PA gene (77,104). In vitro 
transfection of endothelial cells with a retrovirus expressing a 
human t-PA gene resulted in high level secretion of t-PA 
(77,104). One of the main limitations of this strategy, however, 
is the inactivation of recombinant t-PA, resulting from binding 
of t-PA molecules to plasminogen activator inhibitor type 1 
(PAI-1). A single-chain urokinase cDNA, which encodes an 
enzyme that does not bind to PAI-1 has been used to circum- 
vent this limitation (96,105). Taken together, these data sug- 
gest that endothelial cells genetically engineered to produce 
fibrinolytic ompounds such as t-PA may express high levels of 
thrombolytic agent in vitro and, presumably, invivo. Hence, a 
gene transfer protocol in which endothelial cells would be 
directly transfected in vivo using catheter-based local delivery.' 
of adenoviral vectors expressing fibrinolytic molecules may 
augment endothelial antithrombotic activity and ultimately 
prevent thrombus formation at the site of endothelial injury or 
dysfunction. 
Other potential candidates for endothelium-targeted g ne 
therapy await experimental evidence that they may confer 
protection against arterial thrombosis. For example, secretion 
of nitric oxide contributes to the nonthrombogenic surface of 
the normal endothelium (57). Therefore, successful transfec- 
tion of a vulnerable atherosclerotic plaque with cDNA encod- 
ing the constitutive ndothelial nitric oxide synthase (see 
preceding discussion and [58]) may reduce the likelihood of 
arterial thrombosis. 
Alternatively, local delive U of the endothelium-specific 
mitogen vascular endothelial growth factor (VEGF) at the site 
of arterial injury accelerates re-endothelialization a d attenu- 
ates intimal thickening (106). Therefore, it is possible that 
restoration of a potentially antithrombotic (107) endothelial 
layer can be facilitated by transferring the VEGF gene to the 
endoluminal surface of a vulnerable atherosclerotic plaque. 
Successful transfer to the arterial wall of a VEGF-expressing 
plasmid from the surface of a hydrogel-coated balloon catheter 
has been recently reported (108). This genetic strategy has 
several potential advantages over protein therapy: 1) The 
prolonged synthesis and local release of VEGF after gene 
transfer may constitute a more effective means of stimulating 
endothelium regrowth than a single bolus of VEGF protein. 2) 
Relatively inexpensive xpression plasmids encoding for a 
secreted form of VEGF can be designed and may ultimately 
reduce the high costs associated with production of recombi- 
nant proteins. Direct introduction of DNA with no vehicle 
("naked DNA") into the arterial wall has been shown to be 
feasible, although with low efficiency (95). In the case of 
VEGF, however, even low efficiency may prove sufficient o 
induce re-endothelializatitm since the VEGF gene product is. 
in this case, secreted, and therefore capable of modulating 
neighboring cells through a paracrine ffect. Further studies 
are warranted to investigate whether the favorable effect of 
VEGF on abluminal endothelial cells is associated with dele- 
terious intraplaque neoangiogenesis that might predispose to 
plaque hemorrhage. 
Conclusions 
Prevention of acute coronary syndromes represents a major 
challenge for cardiovascular research. Pharmacologic interven- 
tions aimed at lowering serum cholesterol or inhibiting throm- 
bus formation have proved efficient in reducing mortality 
related to acute coronary events. Recent progress in the field 
of gene transfer, as well as a better understanding of the 
pathophysiology of plaque rupture and thrombus formation, 
has established new avenues for a molecular approach to acute 
coronary syndromes. Preliminary results of the first ex vivo 
gene therapy for familial hypercholesterolemia suggest hat 
genetically engineered hepatocytes xpressing the human LDL 
receptor can be introduced into the liver, inducing, in some 
patients, a substantial reduction in serum LDL. However, 
development of more practical protocols using direct admin- 
istration of the LDL receptor gene in vivo are warranted 
before the promise of this technology can be realized. Genetic 
modification of endothelial cells to improve endothelial nti- 
thrombotic activity is a viable alternative. Ultimately, strategies 
that address the concepts of both atherosclerotic plaque 
stabilization and restoration of physiologic endothelial func- 
tions represent an opportune field for future research. 
We gratefully acknowledge the contribution of Dr. David Brown regarding 
investigation of the 92-kDa gelatinase discussed in this review. 
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